Link between Lynch syndrome, hormonal influences, and risk of endometrial cancer
the ONA take:
According to a study published in JAMA, researchers have found an association between the risk of endometrial cancer and the age of first menstrual cycle, having given birth, and hormonal contraceptive use for women with Lynch syndrome.
For the study, researchers analyzed data from 1,128 women with an MMR gene mutation who were included in the Colon Cancer Family Registry. Of those, 133 were diagnosed with endometrial cancer. Results showed that a later age of first menstrual cycle, having given birth, and hormonal contraceptive for 1 year or longer were associated with a reduced risk for developing endometrial cancer. Researchers found no significant association between age at the time of giving first and last birth, age at menopause, and postmenopausal hormonal use and the risk for developing endometrial cancer.
The findings potentially suggest that women with an MMR gene mutation should be counseled on the hormonal influences on the risk of endometrial cancer.
Lynch syndrome is caused by a mutation in one of the MMR genes and between 2% and 5% of endometrial cancer cases are associated with Lynch syndrome.
Researchers have found an association between the risk of endometrial cancer and the age of first menstrual cycle, having given birth, and hormonal contraceptive use for women with Lynch syndrome.
- Ixazomib, a New PI, Offers Improved Efficacy With Acceptable Toxicity Profile for Relapsed/Refractory Multiple Myeloma
- Acupuncture May Improve Fatigue in Patients with Lung Cancer
- "Light" Cigarettes and Cancer Risk (Fact Sheet)
- A Review of CDK4/6 Toxicities and Interactions Management in Breast Cancer
- Vitamin D3 Supplementation Has No Impact on Breast Density Percentage, Breast Cancer Risk
- Dexamethasone-Induced Hiccups in Chemotherapy May be Prevented by Rotating to Methylprednisolone
- New Evidence Shows Metastases May Spread Independently of Lymph Nodes
- Long Term Survivors of Prostate Cancer Express Treatment Decision Regret for Up to 15 Years
- FDA Expands Clearance for Cooling Cap Use With Chemotherapy for Solid Tumors
- Recommendations for Vaccine Administration During Chemotherapy
- Risk for Prostate Cancer Not Associated With Vasectomy, Meta-analysis Affirms
- Disease-Free Survival After Breast Cancer Comparable With Exemestane, Sequential Tamoxifen/Exemestane
- Treating the Other "Patient": Depressive Symptoms Are Predictive of Declining Physical Health in Caregivers
- Oropharyngeal Mucositis Pain Effectively Relieved With Indomethacin Oral Spray
- Opioids Overprescribed in Patients Undergoing Surgery
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|